BOSTON and SHANGHAI, China, Jan. 06, 2022 (GLOBE NEWSWIRE) – Zenas BioPharma, a global biopharma company committed to becoming a leader in the development and delivery of immune-based therapies, today announced the appointment of Dr. John Orloff announced as a board member. Dr. Orloff brings more than 25 years of successfully leading global research and development organizations in a variety of therapeutic areas, including autoimmune diseases, to the Zenas Board of Directors.
“We are very pleased, Dr. To welcome Orloff to the Zenas Board of Directors, ”said Lonnie Moulder, Founder and Executive Chairman of Zenas. “John’s leadership and extensive expertise in research, development, and medical and regulatory affairs will be invaluable as we continue to develop our portfolio of innovative immune-based therapeutics and expand our pipeline through business development.”
“I am delighted to be working with the Zenas leadership team and my fellow board members on the rapid development of an interesting immune-based pipeline for the company,” said Dr. Orloff. “I also look forward to contributing to the further development of the company in its mission to provide innovative medicines to patients in need.”
Dr. Orloff is currently a corporate partner of Agent Capital. In his most recent leadership role, he was Executive Vice President and Head of Research and Development at Alexion, where his leadership role in expanding the development pipeline to 30 programs supported AstraZeneca’s recent acquisition of Alexion for $ 39 billion.
Prior to joining Alexion, Dr. Orloff served as Global Head of R&D and Chief Scientific Officer at Baxalta, and has held executive positions at Novelion, Baxter International, Merck Serono, Novartis and Merck Research Laboratories. Before entering the biopharmaceutical industry, he was a faculty member at Yale University School of Medicine. Dr. Orloff received a bachelor’s degree in chemistry from Dartmouth College, received his medical degree from the University of Vermont, College of Medicine, and an endocrinology and metabolism fellowship from Yale University School of Medicine.
About Zenas BioPharma
Zenas BioPharma is an international US and China based biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies to patients in the US, China and worldwide. Zenas aims to rapidly advance an extensive pipeline of innovative therapeutics through our successful business development strategy. Our experienced leadership team and network of business partners drive our operational excellence so that we can develop transformative therapies that can improve the lives of patients with autoimmune and rare diseases. More information about Zenas BioPharma can be found at www.zenasbio.com and follow us on Twitter @ZenasBioPharma and LinkedIn .
